BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC, Yuan M, Leung WS, Chan JM, Chik TS, Choi CY, Leung K, Chan KH, Chan KC, Li KC, Wu JT, Wilson IA, Monto AS, Poon LL, Peiris M. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill 2020;25. [PMID: 32347204 DOI: 10.2807/1560-7917.ES.2020.25.16.2000421] [Cited by in Crossref: 219] [Cited by in F6Publishing: 238] [Article Influence: 109.5] [Reference Citation Analysis]
Number Citing Articles
1 Kim J, Seo H, Kim H, Kim D, Kwon H, Kim Y. Effect of Previous COVID-19 Vaccination on Humoral Immunity 3 Months after SARS-CoV-2 Omicron Infection and Booster Effect of a Fourth COVID-19 Vaccination 2 Months after SARS-CoV-2 Omicron Infection. Viruses 2022;14:2458. [DOI: 10.3390/v14112458] [Reference Citation Analysis]
2 Omma A, Batirel A, Aydin M, Yilmaz Karadag F, Erden A, Kucuksahin O, Armagan B, Güven SC, Karakas O, Gokdemir S, Altunal LN, Buber AA, Gemcioglu E, Zengin O, Inan O, Sahiner ES, Korukluoglu G, Sezer Z, Ozdarendeli A, Kara A, Ates I. Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Turkey: A randomized trial. Human Vaccines & Immunotherapeutics 2022. [DOI: 10.1080/21645515.2022.2122503] [Reference Citation Analysis]
3 Pecoraro V, Pirotti T, Trenti T. Evidence of SARS-CoV-2 reinfection: analysis of 35,000 subjects and overview of systematic reviews. Clin Exp Med 2022. [PMID: 36289100 DOI: 10.1007/s10238-022-00922-0] [Reference Citation Analysis]
4 Bae DY, Tark D, Moon SH, Oem JK, Kim WI, Park C, Na KJ, Park CK, Oh Y, Cho HS. Evidence of Exposure to SARS-CoV-2 in Dogs and Cats from Households and Animal Shelters in Korea. Animals (Basel) 2022;12:2786. [PMID: 36290173 DOI: 10.3390/ani12202786] [Reference Citation Analysis]
5 Leung D, Mu X, Duque JSR, Cheng SMS, Wang M, Zhang W, Zhang Y, Tam IYS, Lee TSS, Lam JHY, Chan SM, Cheang CH, Chung Y, Wong HHW, Lee AMT, Li WY, Chaothai S, Tsang LCH, Chua GT, Cheong K, Au EYL, Kwok JSY, Chan KW, Chong PCY, Lee PPW, Ho MHK, Lee TL, Tu W, Peiris M, Lau YL. Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity. Front Immunol 2022;13:982155. [DOI: 10.3389/fimmu.2022.982155] [Reference Citation Analysis]
6 Leung D, Chan EY, Mu X, Rosa Duque JS, Cheng SM, Ho FT, Tong P, Lai W, Lee MH, Chim S, Tam IY, Tsang LC, Kwan KK, Chung Y, Wong HH, Lee AM, Li WY, Sze ST, Lam JH, Lee DH, Chan SM, Tu W, Peiris M, Ma AL, Lau YL. Humoral and Cellular Immunogenicity and Safety of 3 Doses of CoronaVac and BNT162b2 in Young Children and Adolescents with Kidney Diseases.. [DOI: 10.1101/2022.09.14.22279916] [Reference Citation Analysis]
7 Zhang W, Li D, Xu B, Xu L, Lyu Q, Liu X, Li Z, Zhang J, Sun W, Ma Q, Qiao L, Liao P. Serum peptidome profiles immune response of COVID-19 Vaccine administration. Front Immunol 2022;13:956369. [DOI: 10.3389/fimmu.2022.956369] [Reference Citation Analysis]
8 SeyedAlinaghi S, Karimi A, Mojdeganlou H, Pashaei Z, Mirzapour P, Shamsabadi A, Barzegary A, Afroughi F, Dehghani S, Janfaza N, Fakhfouri A, Khodaei S, Mehraeen E, Dadras O. Minimum infective dose of severe acute respiratory syndrome coronavirus 2 based on the current evidence: A systematic review. SAGE Open Med 2022;10:20503121221115053. [PMID: 35983085 DOI: 10.1177/20503121221115053] [Reference Citation Analysis]
9 Bagno FF, Sérgio SA, Figueiredo MM, Godoi LC, Andrade LA, Salazar NC, Soares CP, Aguiar A, Almeida FJ, da Silva ED, Ferreira AG, Durigon EL, Gazzinelli RT, Teixeira SM, Fernandes APS, da Fonseca FG. Development and validation of an enzyme-linked immunoassay kit for diagnosis and surveillance of COVID-19. Journal of Clinical Virology Plus 2022;2:100101. [DOI: 10.1016/j.jcvp.2022.100101] [Reference Citation Analysis]
10 Razumikhin M, Smolyanova T, Nikolaeva A, Orlova E, Ivanov A, Belyakova O, Vyaznikova T, Selezneva N, Perevozchikov A, Sokolova A, Zubkova N, Efimova I, Dolzhikova I, Logunov D, Sakanjan E. Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma. Immunotherapy 2022. [PMID: 35892311 DOI: 10.2217/imt-2022-0015] [Reference Citation Analysis]
11 Sui Y, Li J, Andersen H, Zhang R, Prabhu SK, Hoang T, Venzon D, Cook A, Brown R, Teow E, Velasco J, Pessaint L, Moore IN, Lagenaur L, Talton J, Breed MW, Kramer J, Bock KW, Minai M, Nagata BM, Choo-wosoba H, Lewis MG, Wang L, Berzofsky JA. An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques. PNAS Nexus 2022;1. [DOI: 10.1093/pnasnexus/pgac091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Liu K, Han Y, Wu G, Huang KA, Huang P. Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody. Viruses 2022;14:1560. [DOI: 10.3390/v14071560] [Reference Citation Analysis]
13 de Castro Barbosa E, de Souza Andrade A, Duarte MM, Faria G, de Melo Iani FC, Ataide ACZ, Cunha LM, Duarte CG, Fialho SL, Caldas S. Influence of SARS-CoV-2 inactivation by different chemical reagents on the humoral response evaluated in a murine model. Molecular Immunology 2022;147:199-208. [DOI: 10.1016/j.molimm.2022.05.012] [Reference Citation Analysis]
14 Ng SC, Peng Y, Zhang L, Mok CK, Zhao S, Li A, Ching JY, Liu Y, Yan S, Chan DLS, Zhu J, Chen C, Fung AC, Wong KK, Hui DS, Chan FK, Tun HM. Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events. Gut 2022;71:1106-16. [PMID: 35140064 DOI: 10.1136/gutjnl-2021-326563] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
15 Owida HA, Al-nabulsi JI, Turab NM, Louzi N, Zafar A. Nanotechnology Role Development for COVID-19 Pandemic Management. Journal of Nanotechnology 2022;2022:1-12. [DOI: 10.1155/2022/1872933] [Reference Citation Analysis]
16 Kritikos A, Gabellon S, Pagani J, Monti M, Bochud P, Manuel O, Coste A, Greub G, Perreau M, Pantaleo G, Croxatto A, Lamoth F. Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19. Viruses 2022;14:1089. [DOI: 10.3390/v14051089] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
17 Pusterla N, Chaillon A, Ignacio C, Smith DM, Barnum S, Lawton KOY, Smith G, Pickering B. SARS-CoV-2 Seroconversion in an Adult Horse with Direct Contact to a COVID-19 Individual. Viruses 2022;14:1047. [DOI: 10.3390/v14051047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Auerswald H, Eng C, Lay S, In S, Eng S, Vo HTM, Sith C, Cheng S, Delvallez G, Mich V, Meng N, Sovann L, Sidonn K, Vanhomwegen J, Cantaert T, Dussart P, Duong V, Karlsson EA. Rapid Generation of In-House Serological Assays Is Comparable to Commercial Kits Critical for Early Response to Pandemics: A Case With SARS-CoV-2. Front Med 2022;9:864972. [DOI: 10.3389/fmed.2022.864972] [Reference Citation Analysis]
19 Nair D, Raju R, Roy S, Dandge S, Chethrapilly Purushothaman GK, Jayaraman Y, Kangusamy B, Shrivastava R, Arora NK, Rose W, Juvekar S, Jammy GR, Singh K, Mehendale S, Rajkumar P, Malik ST. Sero-Surveillance to Monitor the Trend of SARS-CoV-2 Infection Transmission in India: Study Protocol for a Multi Site, Community Based Longitudinal Cohort Study. Front Public Health 2022;10:810353. [DOI: 10.3389/fpubh.2022.810353] [Reference Citation Analysis]
20 Ransome E, Hobbs F, Jones S, Coleman C, Harris ND, Woodward G, Bell T, Trew J, Kolarević S, Kračun-kolarević M, Savolainen V. No evidence for environmental transmission risk of SARS-CoV-2 in the UK’s largest urban river system: London as a case study.. [DOI: 10.1101/2022.03.16.22272465] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Amara U, Rashid S, Mahmood K, Nawaz MH, Hayat A, Hassan M. Insight into prognostics, diagnostics, and management strategies for SARS CoV-2. RSC Adv 2022;12:8059-94. [PMID: 35424750 DOI: 10.1039/d1ra07988c] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Bagno FF, Andrade LAF, Sérgio SAR, Parise PL, Toledo-teixeira DA, Gazzinelli RT, Fernandes APSM, Teixeira SMR, Granja F, Proença-módena JL, da Fonseca FG. Previous Infection with SARS-CoV-2 Correlates with Increased Protective Humoral Responses after a Single Dose of an Inactivated COVID-19 Vaccine. Viruses 2022;14:510. [DOI: 10.3390/v14030510] [Reference Citation Analysis]
23 Timofeeva A, Sedykh S, Nevinsky G. Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities. Vaccines 2022;10:384. [DOI: 10.3390/vaccines10030384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kay GA, Owen SI, Giorgi E, Clark DJ, Williams CT, Menzies S, Cuevas LE, Davies BMO, Eckersley NM, Hughes GL, Kirwan DE, Krishna S, Patterson EI, Planche T, Staines HM, Adams ER. SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests. Sci Rep 2022;12:3351. [PMID: 35233014 DOI: 10.1038/s41598-022-07263-8] [Reference Citation Analysis]
25 Aziz H, Fatima S, Mahmood H, Muhammad S, Saeed MA, Khurshid S, Aslam W, Aziz S, Faheem M. Antibody Response to SARS-CoV-2 in Relation to the Contributing Factors in COVID-19 Patients. Viral Immunol 2022. [PMID: 35167759 DOI: 10.1089/vim.2021.0097] [Reference Citation Analysis]
26 Kichatova VS, Asadi Mobarkhan FA, Potemkin IA, Zlobin SP, Perfilieva OM, Valuev-elliston VT, Ivanov AV, Solonin SA, Godkov MA, Belikova MG, Mikhailov MI, Kyuregyan KK. Assessment of Diagnostic Specificity of Anti-SARS-CoV-2 Antibody Tests and Their Application for Monitoring of Seroconversion and Stability of Antiviral Antibody Response in Healthcare Workers in Moscow. Microorganisms 2022;10:429. [DOI: 10.3390/microorganisms10020429] [Reference Citation Analysis]
27 Lap-tak Ma A, Leung D, Yu-hin Chan E, Chim S, Cheng S, Tsz-wai Ho F, Lai W, Tong P, Hon-lam Lee M, Hing-sang Wong W, Chan SM, Duque JR, Malik Peiris JS, Lau Y. Antibody responses to 2 doses of mRNA Covid vaccine in pediatric renal patients. Kidney International 2022. [DOI: 10.1016/j.kint.2022.01.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
28 Jawalagatti V, Kirthika P, Park J, Hewawaduge C, Lee JH. Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection. Journal of Advanced Research 2022;36:211-22. [DOI: 10.1016/j.jare.2021.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
29 Macedo ACL, Prestes GDS, Colonetti T, Candido ACR, Uggioni MLR, Gomes AC, Silva FR, Ceretta LB, Grande AJ, da Rosa MI. A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE ACCURACY OF SARS-COV-2 IGM AND IGG TESTS IN INDIVIDUALS WITH COVID-19. Journal of Clinical Virology 2022. [DOI: 10.1016/j.jcv.2022.105121] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Leung NHL, Cheng SMS, Martín-sánchez M, Au NYM, Ng YY, Luk LLH, Chan KCK, Li JKC, Leung YWY, Tsang LCH, Chaothai S, Kwan KKH, Ip DKM, Poon LLM, Leung GM, Malik Peiris JS, Cowling BJ. Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine.. [DOI: 10.1101/2022.01.20.22269586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Kwok SL, Cheng SM, Leung JN, Leung K, Lee CK, Peiris JM, Wu JT. Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021. Euro Surveill 2022;27. [PMID: 35027105 DOI: 10.2807/1560-7917.ES.2022.27.2.2101197] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
32 Chen Y, Li C, Liu F, Ye Z, Song W, Lee ACY, Shuai H, Lu L, To KK, Chan JF, Zhang AJ, Chu H, Yuen KY. Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in mouse model. Emerg Microbes Infect 2022;:1-36. [PMID: 34989330 DOI: 10.1080/22221751.2022.2026741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
33 Zhang Y, Ding D. Portable and visual assays for the detection of SARS‐CoV‐2. VIEW 2022;3:20200138. [DOI: 10.1002/viw.20200138] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Xu Z, Ho M, Bordoloi D, Kudchodkar S, Khoshnejad M, Giron L, Zaidi F, Jeong M, Roberts CC, Park YK, Maslow J, Abdel-mohsen M, Muthumani K. Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases. Vaccine Design 2022. [DOI: 10.1007/978-1-0716-1884-4_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Shim SM, Kim JW, Jung S, Jung Y, Woo HM, Yang JS, Kim KC, Lee JY. Persistence of the neutralising antibody response after SARS-CoV-2 infection. Clin Microbiol Infect 2021:S1198-743X(21)00720-5. [PMID: 34954127 DOI: 10.1016/j.cmi.2021.12.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Heggestad JT, Britton RJ, Kinnamon DS, Wall SA, Joh DY, Hucknall AM, Olson LB, Anderson JG, Mazur A, Wolfe CR, Oguin TH 3rd, Sullenger BA, Burke TW, Kraft BD, Sempowski GD, Woods CW, Chilkoti A. Rapid test to assess the escape of SARS-CoV-2 variants of concern. Sci Adv 2021;7:eabl7682. [PMID: 34860546 DOI: 10.1126/sciadv.abl7682] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
37 Gilboa T, Cohen L, Cheng C, Lazarovits R, Uwamanzu‐nna A, Han I, Griswold K, Barry N, Thompson DB, Kohman RE, Woolley AE, Karlson EW, Walt DR. A SARS‐CoV‐2 Neutralization Assay Using Single Molecule Arrays. Angewandte Chemie 2021;133:26170-26176. [DOI: 10.1002/ange.202110702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
38 Hayashi K, Asai S, Umezawa K, Kakizoe H, Miyachi H, Morita M, Akaike T, Kuno H, Komatsu S, Watanabe T, Kawahara T. Virucidal effect of monogalactosyl diacylglyceride from a green microalga, Coccomyxa sp. KJ, against clinical isolates of SARS-CoV-2 as assessed by a plaque assay. J Clin Lab Anal 2021;:e24146. [PMID: 34837712 DOI: 10.1002/jcla.24146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Jung BK, Yoon J, Bae JY, Kim J, Park MS, Lee SY, Lim CS. Performance Evaluation of the BZ COVID-19 Neutralizing Antibody Test for the Culture-Free and Rapid Detection of SARS-CoV-2 Neutralizing Antibodies. Diagnostics (Basel) 2021;11:2193. [PMID: 34943430 DOI: 10.3390/diagnostics11122193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Morales-Núñez JJ, Muñoz-Valle JF, Torres-Hernández PC, Hernández-Bello J. Overview of Neutralizing Antibodies and Their Potential in COVID-19. Vaccines (Basel) 2021;9:1376. [PMID: 34960121 DOI: 10.3390/vaccines9121376] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
41 Devi YD, Goswami HB, Konwar S, Doley C, Dolley A, Devi A, Chongtham C, Dowerah D, Biswa V, Jamir L, Kumar A, Satapathy SS, Ray SK, Deka RC, Doley R, Mandal M, Das S, Singh CS, Borah PP, Nath P, Namsa ND. Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins. PLoS One 2021;16:e0258645. [PMID: 34780495 DOI: 10.1371/journal.pone.0258645] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Lau EH, Hui DS, Tsang OT, Chan WH, Kwan MY, Chiu SS, Cheng SM, Ko RL, Li JK, Chaothai S, Tsang CH, Poon LL, Peiris M. Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. EClinicalMedicine 2021;41:101174. [PMID: 34746725 DOI: 10.1016/j.eclinm.2021.101174] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 26.0] [Reference Citation Analysis]
43 Mahmoud SA, Ganesan S, Naik S, Bissar S, Zamel IA, Warren KN, Zaher WA, Khan G. Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response. Microbiol Spectr 2021;9:e0073321. [PMID: 34585943 DOI: 10.1128/Spectrum.00733-21] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
44 Ha B, Jadhao S, Hussaini L, Gibson T, Stephens K, Salazar L, Ciric C, Taylor M, Rouphael N, Edupuganti S, Rostad CA, Tompkins SM, Anderson EJ, Anderson LJ. Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera. Microbiol Spectr 2021;9:e0045821. [PMID: 34494855 DOI: 10.1128/Spectrum.00458-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Yilmaz A, Kayar A, Turan N, Iskefli O, Bayrakal A, Roman-Sosa G, Or E, Tali HE, Kocazeybek B, Karaali R, Bold D, Sadeyen JR, Lukosaityte D, Chang P, Iqbal M, Richt JA, Yilmaz H. Presence of Antibodies to SARS-CoV-2 in Domestic Cats in Istanbul, Turkey, Before and After COVID-19 Pandemic. Front Vet Sci 2021;8:707368. [PMID: 34712718 DOI: 10.3389/fvets.2021.707368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
46 Pérez-Tanoira R, Lledó García L, Torralba González de Suso M, Rodríguez Zapata M, Arroyo Serrano T, Giménez Pardo C, Rodríguez Pedrosa MI, Romero Badía MN, Pérez-García F, González López P, Villaescusa García C, Cuadros González J. High Seroprevalence Against SARS-CoV-2 Among Faculty of Medicine and Health Sciences Personnel and Students of the University of Alcalá, Spain: Contributing Factors. Int J Gen Med 2021;14:7017-24. [PMID: 34707393 DOI: 10.2147/IJGM.S332803] [Reference Citation Analysis]
47 Sui Y, Li J, Andersen H, Zhang R, Prabhu SK, Hoang T, Venzon D, Cook A, Brown R, Teow E, Velasco J, Pessaint L, Moore IN, Lagenaur L, Talton J, Breed MW, Kramer J, Bock KW, Minai M, Nagata BM, Choo-wosoba H, Lewis MG, Wang L, Berzofsky JA. An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant viral replication in rhesus macaques.. [DOI: 10.1101/2021.10.19.464990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Lo Muzio L, Ambosino M, Lo Muzio E, Quadri MFA. SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature. Int J Environ Res Public Health 2021;18:11001. [PMID: 34682746 DOI: 10.3390/ijerph182011001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
49 Mrzljak A, Jureković Ž, Pavičić-Šarić J, Stevanović V, Tabain I, Hruškar Ž, Mikulić D, Barbić L, Vilibić-Čavlek T. Seroprevalence of SARS-CoV-2 in Croatian solid-organ transplant recipients. Biochem Med (Zagreb) 2021;31:030901. [PMID: 34658649 DOI: 10.11613/BM.2021.030901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Forgacs D, Jang H, Abreu RB, Hanley HB, Gattiker JL, Jefferson AM, Ross TM. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans. Front Immunol 2021;12:728021. [PMID: 34646267 DOI: 10.3389/fimmu.2021.728021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
51 Pinilla YT, Friessinger E, Griesbaum JM, Berner L, Heinzel C, Elsner K, Fendel R, Held J, Kreidenweiss A. Prevalence of SARS-CoV-2 Infection in Children by Antibody Detection in Saliva: Protocol for a Prospective Longitudinal Study (Coro-Buddy). JMIR Res Protoc 2021;10:e27739. [PMID: 34533472 DOI: 10.2196/27739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Li X, Liang C, Xiao X. SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration. Vaccines (Basel) 2021;9:1139. [PMID: 34696247 DOI: 10.3390/vaccines9101139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
53 Larsen SE, Berube BJ, Pecor T, Cross E, Brown BP, Williams BD, Johnson E, Qu P, Carter L, Wrenn S, Kepl E, Sydeman C, King NP, Baldwin SL, Coler RN. Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples. J Immunol Methods 2021;499:113160. [PMID: 34599915 DOI: 10.1016/j.jim.2021.113160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
54 Gomes Noll JC, do Nascimento GM, Diel DG. Natural Transmission and Experimental Models of SARS CoV-2 Infection in Animals. Comp Med 2021;71:369-82. [PMID: 34702427 DOI: 10.30802/AALAS-CM-21-000046] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Meir J, Abid MA, Abid MB. State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses. Transplant Cell Ther 2021:S2666-6367(21)01258-6. [PMID: 34587552 DOI: 10.1016/j.jtct.2021.09.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
56 de la Guardia C, Rangel G, Villarreal A, Goodridge A, Fernández PL, Lleonart R. Development of in-house, indirect ELISAs for the detection of SARS-CoV-2 spike protein-associated serology in COVID-19 patients in Panama. PLoS One 2021;16:e0257351. [PMID: 34520491 DOI: 10.1371/journal.pone.0257351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
57 Popova AY, Smirnov VS, Andreeva EE, Babura EA, Balakhonov SV, Bashketova NS, Bugorkova SA, Bulanov MV, Valeullina NN, Vetrov VV, Goryaev DV, Detkovskaya TN, Ezhlova EB, Zaitseva NN, Istorik OA, Kovalchuk IV, Kozlovskikh DN, Kombarova SY, Kurganova OP, Lomovtsev AE, Lukicheva LA, Lyalina LV, Melnikova AA, Mikailova OM, Noskov AK, Noskova LN, Oglezneva EE, Osmolovskaya TP, Patyashina MA, Penkovskaya NA, Samoilova LV, Stepanova TF, Trotsenko OE, Totolian AA. SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic. Viruses 2021;13:1648. [PMID: 34452512 DOI: 10.3390/v13081648] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
58 Bradley BT, Bryan A, Fink SL, Goecker EA, Roychoudhury P, Huang ML, Zhu H, Chaudhary A, Madarampalli B, Lu JYC, Strand K, Whimbey E, Bryson-Cahn C, Schippers A, Mani NS, Pepper G, Jerome KR, Morishima C, Coombs RW, Wener M, Cohen S, Greninger AL. Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity. J Clin Microbiol 2021;59:e0098921. [PMID: 34165323 DOI: 10.1128/JCM.00989-21] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 26.0] [Reference Citation Analysis]
59 Ast V, Costina V, Eichner R, Bode A, Aida S, Gerhards C, Thiaucourt M, Dobler G, Geilenkeuser WJ, Wölfel R, Neumaier M, Haselmann V. Assessing the Quality of Serological Testing in the COVID-19 Pandemic: Results of a European External Quality Assessment (EQA) Scheme for Anti-SARS-CoV-2 Antibody Detection. J Clin Microbiol 2021;59:e0055921. [PMID: 34190575 DOI: 10.1128/JCM.00559-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
60 Kalkeri R, Cai Z, Lin S, Farmer J, Kuzmichev YV, Koide F. SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes. Microorganisms 2021;9:1744. [PMID: 34442823 DOI: 10.3390/microorganisms9081744] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
61 Hamady A, Lee J, Loboda ZA. Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses? Infection 2021. [PMID: 34324165 DOI: 10.1007/s15010-021-01664-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 21.0] [Reference Citation Analysis]
62 Ni Y, Rosier BJHM, van Aalen EA, Hanckmann ETL, Biewenga L, Pistikou AM, Timmermans B, Vu C, Roos S, Arts R, Li W, de Greef TFA, van Borren MMGJ, van Kuppeveld FJM, Bosch BJ, Merkx M. A plug-and-play platform of ratiometric bioluminescent sensors for homogeneous immunoassays. Nat Commun 2021;12:4586. [PMID: 34321486 DOI: 10.1038/s41467-021-24874-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 22.0] [Reference Citation Analysis]
63 Yuan S, Jiang SC, Zhang ZW, Fu YF, Hu J, Li ZL. The Role of Alveolar Edema in COVID-19. Cells 2021;10:1897. [PMID: 34440665 DOI: 10.3390/cells10081897] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
64 Gong F, Wei HX, Li Q, Liu L, Li B. Evaluation and Comparison of Serological Methods for COVID-19 Diagnosis. Front Mol Biosci 2021;8:682405. [PMID: 34368226 DOI: 10.3389/fmolb.2021.682405] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 16.0] [Reference Citation Analysis]
65 Stevanovic V, Tabain I, Vilibic-Cavlek T, Mauric Maljkovic M, Benvin I, Hruskar Z, Kovac S, Smit I, Miletic G, Hadina S, Staresina V, Radin L, Plichta V, Skrlin B, Vrbanac Z, Brkljacic M, Cvetnic M, Habus J, Martinkovic K, Zecevic I, Jurkic G, Ferencak I, Stritof Z, Perharic M, Bucic L, Barbic L. The Emergence of SARS-CoV-2 within the Dog Population in Croatia: Host Factors and Clinical Outcome. Viruses 2021;13:1430. [PMID: 34452296 DOI: 10.3390/v13081430] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
66 Kalkeri R, Cai Z, Lin S, Farmer J, Kuzmichev YV, Koide F. SARS-CoV-2 Spike Pseudoviruses: A Useful tool to study virus entry and address emerging neutralization escape phenotypes.. [DOI: 10.1101/2021.07.16.452709] [Reference Citation Analysis]
67 Nguyen D, Simmonds P, Steenhuis M, Wouters E, Desmecht D, Garigliany M, Romano M, Barbezange C, Maes P, Van Holm B, Mendoza J, Oyonarte S, Fomsgaard A, Lassaunière R, Zusinaite E, Resman Rus K, Avšič-Županc T, Reimerink JH, Brouwer F, Hoogerwerf M, Reusken CB, Grodeland G, Le Cam S, Gallian P, Amroun A, Brisbarre N, Martinaud C, Leparc Goffart I, Schrezenmeier H, Feys HB, van der Schoot CE, Harvala H. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Euro Surveill 2021;26. [PMID: 34240697 DOI: 10.2807/1560-7917.ES.2021.26.27.2100568] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
68 Saud M, Ashfaq A, Abbas A, Ariadi S, Mahmood QK. Social support through religion and psychological well-being: COVID-19 and coping strategies in Indonesia. J Relig Health 2021. [PMID: 34245436 DOI: 10.1007/s10943-021-01327-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
69 Rasmi Y, Saloua KS, Nemati M, Choi JR. Recent Progress in Nanotechnology for COVID-19 Prevention, Diagnostics and Treatment. Nanomaterials (Basel) 2021;11:1788. [PMID: 34361174 DOI: 10.3390/nano11071788] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
70 Souza WM, Amorim MR, Sesti-Costa R, Coimbra LD, Brunetti NS, Toledo-Teixeira DA, de Souza GF, Muraro SP, Parise PL, Barbosa PP, Bispo-Dos-Santos K, Mofatto LS, Simeoni CL, Claro IM, Duarte ASS, Coletti TM, Zangirolami AB, Costa-Lima C, Gomes ABSP, Buscaratti LI, Sales FC, Costa VA, Franco LAM, Candido DS, Pybus OG, de Jesus JG, Silva CAM, Ramundo MS, Ferreira GM, Pinho MC, Souza LM, Rocha EC, Andrade PS, Crispim MAE, Maktura GC, Manuli ER, Santos MNN, Camilo CC, Angerami RN, Moretti ML, Spilki FR, Arns CW, Addas-Carvalho M, Benites BD, Vinolo MAR, Mori MAS, Gaburo N, Dye C, Marques-Souza H, Marques RE, Farias AS, Diamond MS, Faria NR, Sabino EC, Granja F, Proença-Módena JL. Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. Lancet Microbe 2021. [PMID: 34258603 DOI: 10.1016/S2666-5247(21)00129-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 54.0] [Reference Citation Analysis]
71 Awada C, Abdullah MMB, Traboulsi H, Dab C, Alshoaibi A. SARS-CoV-2 Receptor Binding Domain as a Stable-Potential Target for SARS-CoV-2 Detection by Surface-Enhanced Raman Spectroscopy. Sensors (Basel) 2021;21:4617. [PMID: 34283162 DOI: 10.3390/s21134617] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
72 Larsen SE, Berube BJ, Pecor T, Cross E, Brown BP, Williams B, Johnson E, Qu P, Carter L, Wrenn S, Kepl E, Sydeman C, King NP, Baldwin SL, Coler RN. Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples. bioRxiv 2021:2021. [PMID: 34230930 DOI: 10.1101/2021.07.02.450915] [Reference Citation Analysis]
73 Bagno FF, Sérgio SAR, Figueiredo MM, Godoi LC, Andrade LAF, Salazar NC, Soares CP, Aguiar A, Almeida FJ, da Silva ED, Ferreira AGP, Durigon EL, Gazzinelli RT, Teixeira SMR, Fernandes APSM, da Fonseca FG. DEVELOPMENT AND VALIDATION OF AN ENZYME-LINKED IMMUNOASSAY KIT FOR DIAGNOSIS AND SURVEILLANCE OF COVID-19.. [DOI: 10.1101/2021.06.23.21259392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
74 Lu Y, Wang J, Li Q, Hu H, Lu J, Chen Z. Advances in Neutralization Assays for SARS‐CoV‐2. Scand J Immunol 2021;94. [DOI: 10.1111/sji.13088] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 22.0] [Reference Citation Analysis]
75 Vandergaast R, Carey T, Reiter S, Lathrum C, Lech P, Gnanadurai C, Haselton M, Buehler J, Narjari R, Schnebeck L, Roesler A, Sevola K, Suksanpaisan L, Bexon A, Naik S, Brunton B, Weaver SC, Rafael G, Tran S, Baum A, Kyratsous CA, Peng KW, Russell SJ. IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers. mSphere 2021;6:e0017021. [PMID: 34077262 DOI: 10.1128/mSphere.00170-21] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
76 Yu S, Chen K, Fang L, Mao H, Lou X, Li C, Zhang Y. Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. Vaccines (Basel) 2021;9:588. [PMID: 34199384 DOI: 10.3390/vaccines9060588] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
77 Ogundipe HD. HUMORAL IMMUNITY IN PATIENTS WITH SARS-COV-2 INFECTION: A REVIEW. Ann Ib Postgrad Med 2021;19:S77-82. [PMID: 35095374] [Reference Citation Analysis]
78 Forgacs D, Jang H, Abreu RB, Hanley HB, Gattiker JL, Jefferson AM, Ross TM. Functional characterization of SARS-CoV-2 vaccine elicited antibodies in immunologically naïve and pre-immune humans. bioRxiv 2021:2021. [PMID: 34100015 DOI: 10.1101/2021.05.29.445137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Tolah AMK, Sohrab SS, Tolah KMK, Hassan AM, El-Kafrawy SA, Azhar EI. Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay. Diagnostics (Basel) 2021;11:994. [PMID: 34070824 DOI: 10.3390/diagnostics11060994] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
80 Keaney D, Whelan S, Finn K, Lucey B. Misdiagnosis of SARS-CoV-2: A Critical Review of the Influence of Sampling and Clinical Detection Methods. Med Sci (Basel) 2021;9:36. [PMID: 34070530 DOI: 10.3390/medsci9020036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
81 Zyad M, Bouikhalene B, Zyad A. Convolutional Neural Network Approach in Covid-19 Screening in Asymptomatic Individuals. 2021 7th International Conference on Optimization and Applications (ICOA) 2021. [DOI: 10.1109/icoa51614.2021.9442641] [Reference Citation Analysis]
82 Charlton C, Kanji J, Tran V, Kus J, Gubbay J, Osiowy C, Robinson J, Sekirov I, Drebot M, Hatchette T, Stein D, El-Gabalawy N, Lang A, Jiao L, Levett P, Wood H, Therrien C, Lindsay LR, Morshed M, Forbes J, Dibernardo A. Practical guidance for clinical laboratories for SARS-CoV-2 serology testing. Can Commun Dis Rep 2021;47:171-83. [PMID: 34035663 DOI: 10.14745/ccdr.v47i04a01] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
83 Sebastião CS, Galangue M, Gaston C, Van-Dunen R, Jandondo D, Neto Z, de Vasconcelos JN, Morais J. Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola. Health Sci Rep 2021;4:e280. [PMID: 33977162 DOI: 10.1002/hsr2.280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
84 de la Guardia C, Rangel G, Villarreal A, Goodridge A, Fernández PL, Lleonart R. Development of in-house, indirect ELISAs for the detection of SARS-CoV-2 spike protein-associated serology in COVID-19 patients in Panama.. [DOI: 10.1101/2021.04.30.21256406] [Reference Citation Analysis]
85 Lewin A, Drews SJ, Lieshout-Krikke R, Erikstrup C, Saeed S, Fady H, Uzicanin S, Custer B, O'Brien SF; Surveillance, Risk Assessment, Policy, the Virology Sub-groups of the ISBT Transfusion Transmitted Infectious Diseases Working Party. An international comparison of anti-SARS-COV-2 assays used for seroprevalence surveys from blood component providers. Vox Sang 2021. [PMID: 33914918 DOI: 10.1111/vox.13100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
86 Sui Y, Li J, Zhang R, Prabhu SK, Andersen H, Venzon D, Cook A, Brown R, Teow E, Velasco J, Greenhouse J, Putman-Taylor T, Campbell TA, Pessaint L, Moore IN, Lagenaur L, Talton J, Breed MW, Kramer J, Bock KW, Minai M, Nagata BM, Lewis MG, Wang LX, Berzofsky JA. Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. JCI Insight 2021;6:148494. [PMID: 33908897 DOI: 10.1172/jci.insight.148494] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 21.0] [Reference Citation Analysis]
87 Nagura-Ikeda M, Imai K, Kubota K, Noguchi S, Kitagawa Y, Matsuoka M, Tabata S, Miyoshi K, Ito T, Tamura K, Maeda T. Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan. J Med Microbiol 2021;70. [PMID: 33861191 DOI: 10.1099/jmm.0.001291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
88 Guo L, Wang Y, Kang L, Hu Y, Wang L, Zhong J, Chen H, Ren L, Gu X, Wang G, Wang C, Dong X, Wu C, Han L, Wang Y, Fan G, Zou X, Li H, Xu J, Jin Q, Cao B, Wang J. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerg Microbes Infect 2021;10:664-76. [PMID: 33734013 DOI: 10.1080/22221751.2021.1905488] [Cited by in Crossref: 47] [Cited by in F6Publishing: 29] [Article Influence: 47.0] [Reference Citation Analysis]
89 Aziz NA, Corman VM, Echterhoff AKC, Müller MA, Richter A, Schmandke A, Schmidt ML, Schmidt TH, de Vries FM, Drosten C, Breteler MMB. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. Nat Commun 2021;12:2117. [PMID: 33837204 DOI: 10.1038/s41467-021-22351-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 47.0] [Reference Citation Analysis]
90 Müller K, Girl P, Ruhnke M, Spranger M, Kaier K, von Buttlar H, Dobler G, Borde JP. SARS-CoV-2 Seroprevalence among Health Care Workers-A Voluntary Screening Study in a Regional Medical Center in Southern Germany. Int J Environ Res Public Health 2021;18:3910. [PMID: 33917840 DOI: 10.3390/ijerph18083910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
91 Liu G, Rusling JF. COVID-19 Antibody Tests and Their Limitations. ACS Sens 2021;6:593-612. [PMID: 33544999 DOI: 10.1021/acssensors.0c02621] [Cited by in Crossref: 76] [Cited by in F6Publishing: 59] [Article Influence: 76.0] [Reference Citation Analysis]
92 Mendoza R, Silver M, Zuretti AR, Christian M, Das B, Norin AJ, Borgen P, Libien J, Bluth MH. Correlation of Automated Chemiluminescent Method with Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titers in Convalescent COVID-19 Plasma Samples: Development of Rapid, Cost-Effective Semi-Quantitative Diagnostic Methods. J Blood Med 2021;12:157-64. [PMID: 33762863 DOI: 10.2147/JBM.S296730] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
93 Neerukonda SN, Vassell R, Herrup R, Liu S, Wang T, Takeda K, Yang Y, Lin TL, Wang W, Weiss CD. Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLoS One 2021;16:e0248348. [PMID: 33690649 DOI: 10.1371/journal.pone.0248348] [Cited by in Crossref: 66] [Cited by in F6Publishing: 73] [Article Influence: 66.0] [Reference Citation Analysis]
94 Yadav PD, Ella R, Kumar S, Patil DR, Mohandas S, Shete AM, Vadrevu KM, Bhati G, Sapkal G, Kaushal H, Patil S, Jain R, Deshpande G, Gupta N, Agarwal K, Gokhale M, Mathapati B, Metkari S, Mote C, Nyayanit D, Patil DY, Sai Prasad BS, Suryawanshi A, Kadam M, Kumar A, Daigude S, Gopale S, Majumdar T, Mali D, Sarkale P, Baradkar S, Gawande P, Joshi Y, Fulari S, Dighe H, Sharma S, Gunjikar R, Kumar A, Kalele K, Srinivas VK, Gangakhedkar RR, Ella KM, Abraham P, Panda S, Bhargava B. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Nat Commun 2021;12:1386. [PMID: 33654090 DOI: 10.1038/s41467-021-21639-w] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 40.0] [Reference Citation Analysis]
95 Qin X, Shen J, Dai E, Li H, Tang G, Zhang L, Hou X, Lu M, Wu X, Duan S, Zhang J, Tsoi MF, Jiang P, Li Y. The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19. BMC Immunol 2021;22:14. [PMID: 33596826 DOI: 10.1186/s12865-021-00404-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
96 Gasser R, Cloutier M, Prévost J, Fink C, Ducas É, Ding S, Dussault N, Landry P, Tremblay T, Laforce-Lavoie A, Lewin A, Beaudoin-Bussières G, Laumaea A, Medjahed H, Larochelle C, Richard J, Dekaban GA, Dikeakos JD, Bazin R, Finzi A. Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. Cell Rep 2021;34:108790. [PMID: 33596407 DOI: 10.1016/j.celrep.2021.108790] [Cited by in Crossref: 64] [Cited by in F6Publishing: 72] [Article Influence: 64.0] [Reference Citation Analysis]
97 Li Z, Guan X, Mao N, Luo H, Qin Y, He N, Zhu Z, Yu J, Li Y, Liu J, An Z, Gao W, Wang X, Sun X, Song T, Yang X, Wu M, Wu X, Yao W, Peng Z, Sun J, Wang L, Guo Q, Xiang N, Liu J, Zhang B, Su X, Rodewald L, Li L, Xu W, Shen H, Feng Z, Gao GF. Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China. Lancet Reg Health West Pac 2021;8:100094. [PMID: 33585828 DOI: 10.1016/j.lanwpc.2021.100094] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 27.0] [Reference Citation Analysis]
98 Pinilla YT, Friessinger E, Griesbaum JM, Berner L, Heinzel C, Elsner K, Fendel R, Held J, Kreidenweiss A. Prevalence of SARS-CoV-2 Infection in Children by Antibody Detection in Saliva: Protocol for a Prospective Longitudinal Study (Coro-Buddy) (Preprint).. [DOI: 10.2196/preprints.27739] [Reference Citation Analysis]
99 Perera RAPM, Ko R, Tsang OTY, Hui DSC, Kwan MYM, Brackman CJ, To EMW, Yen HL, Leung K, Cheng SMS, Chan KH, Chan KCK, Li KC, Saif L, Barrs VR, Wu JT, Sit THC, Poon LLM, Peiris M. Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera. J Clin Microbiol 2021;59:e02504-20. [PMID: 33139421 DOI: 10.1128/JCM.02504-20] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 54.0] [Reference Citation Analysis]
100 Fu Y, Pan Y, Li Z, Li Y. The Utility of Specific Antibodies Against SARS-CoV-2 in Laboratory Diagnosis. Front Microbiol 2020;11:603058. [PMID: 33519745 DOI: 10.3389/fmicb.2020.603058] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
101 Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, Ko RLW, Chan KH, Cheng SMS, Perera RAPM, Cowling BJ, Poon LLM, Peiris M. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun 2021;12:63. [PMID: 33397909 DOI: 10.1038/s41467-020-20247-4] [Cited by in Crossref: 209] [Cited by in F6Publishing: 215] [Article Influence: 209.0] [Reference Citation Analysis]
102 Sinha V, Saxena S, Pandey SK, Dwivedi S, Thakur S, Asea A, Dixit AK, Dixit V, Vishvakarma NK, Shukla D. Current Challenges for the Effective Management of the COVID-19 Pandemic. Coronavirus Therapeutics – Volume II 2021. [DOI: 10.1007/978-3-030-85113-2_8] [Reference Citation Analysis]
103 Bu J, Deng Z, Liu H, Li J, Wang, Yang Y, Zhong S. Current methods and prospects of coronavirus detection. Talanta 2021;225:121977. [PMID: 33592725 DOI: 10.1016/j.talanta.2020.121977] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
104 Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, Rigby S, Williams SV, Bermingham WH, Kellam P, Maher J, Shields AM, Amirthalingam G, Peacock SJ, Ismail SA. Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS One 2020;15:e0244126. [PMID: 33382764 DOI: 10.1371/journal.pone.0244126] [Cited by in Crossref: 186] [Cited by in F6Publishing: 200] [Article Influence: 93.0] [Reference Citation Analysis]
105 Rehman MFU, Fariha C, Anwar A, Shahzad N, Ahmad M, Mukhtar S, Farhan Ul Haque M. Novel coronavirus disease (COVID-19) pandemic: A recent mini review. Comput Struct Biotechnol J 2021;19:612-23. [PMID: 33398233 DOI: 10.1016/j.csbj.2020.12.033] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
106 Wang R, Luo X, Liu F, Luo S. Confronting the threat of SARS-CoV-2: Realities, challenges and therapeutic strategies (Review). Exp Ther Med 2021;21:155. [PMID: 33456522 DOI: 10.3892/etm.2020.9587] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
107 Harvala H, Robb ML, Watkins N, Ijaz S, Dicks S, Patel M, Supasa P, Wanwisa D, Liu C, Mongkolsapaya J, Bown A, Bailey D, Vipond R, Grayson N, Temperton N, Gupta S, Ploeg RJ, Bolton J, Fyfe A, Gopal R, Simmonds P, Screaton G, Thompson C, Brooks T, Zambon M, Miflin G, Roberts DJ. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfus Med 2021;31:167-75. [PMID: 33333627 DOI: 10.1111/tme.12746] [Cited by in Crossref: 35] [Cited by in F6Publishing: 49] [Article Influence: 17.5] [Reference Citation Analysis]
108 Akinshina YA, Mardanly SS, Kiseleva VA. Immunochromatographic test for differentiation detection of IgM and IgG to SARS-CoV-2. Klin Lab Diagn 2020;65:688-92. [PMID: 33301658 DOI: 10.18821/0869-2084-2020-65-11-688-692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Rodríguez Hernández C, Sanz Moreno L. [Immunity against SARS-CoV-2: walking to the vaccination]. Rev Esp Quimioter 2020;33:392-8. [PMID: 32935536 DOI: 10.37201/req/086.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
110 Indenbaum V, Koren R, Katz-Likvornik S, Yitzchaki M, Halpern O, Regev-Yochay G, Cohen C, Biber A, Feferman T, Cohen Saban N, Dhan R, Levin T, Gozlan Y, Weil M, Mor O, Mandelboim M, Sofer D, Mendelson E, Lustig Y. Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis. PLoS One 2020;15:e0241164. [PMID: 33227020 DOI: 10.1371/journal.pone.0241164] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 17.0] [Reference Citation Analysis]
111 Gundlapalli AV, Salerno RM, Brooks JT, Averhoff F, Petersen LR, McDonald LC, Iademarco MF; CDC COVID-19 Response . SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response. Open Forum Infect Dis 2021;8:ofaa555. [PMID: 33442555 DOI: 10.1093/ofid/ofaa555] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 20.5] [Reference Citation Analysis]
112 Koblischke M, Traugott MT, Medits I, Spitzer FS, Zoufaly A, Weseslindtner L, Simonitsch C, Seitz T, Hoepler W, Puchhammer-Stöckl E, Aberle SW, Födinger M, Bergthaler A, Kundi M, Heinz FX, Stiasny K, Aberle JH. Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity. Front Med (Lausanne) 2020;7:592629. [PMID: 33262993 DOI: 10.3389/fmed.2020.592629] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 17.5] [Reference Citation Analysis]
113 Padoan A, Bonfante F, Pagliari M, Bortolami A, Negrini D, Zuin S, Bozzato D, Cosma C, Sciacovelli L, Plebani M. Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity. EBioMedicine 2020;62:103101. [PMID: 33160207 DOI: 10.1016/j.ebiom.2020.103101] [Cited by in Crossref: 104] [Cited by in F6Publishing: 106] [Article Influence: 52.0] [Reference Citation Analysis]
114 Ni Y, Rosier BJ, van Aalen EA, Hanckmann ET, Biewenga L, Pistikou AM, Timmermans B, Vu C, Roos S, Arts R, Li W, de Greef TF, van Kuppeveld FJM, Bosch B, Merkx M. RAPPID: a platform of ratiometric bioluminescent sensors for homogeneous immunoassays.. [DOI: 10.1101/2020.10.31.363044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
115 Mazumder S, Rastogi R, Undale A, Arora K, Arora NM, Pratim B, Kumar D, Joseph A, Mali B, Arya VB, Kalyanaraman S, Mukherjee A, Gupta A, Potdar S, Roy SS, Parashar D, Paliwal J, Singh SK, Naqvi A, Srivastava A, Singh MK, Kumar D, Bansal S, Rautray S, Singh I, Fengade P, Kumar B, Saini M, Jain K, Gupta R, Kundu PK. PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2.. [DOI: 10.1101/2020.10.30.360115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 Premraj A, Aleyas AG, Nautiyal B, Rasool TJ. Nucleic Acid and Immunological Diagnostics for SARS-CoV-2: Processes, Platforms and Pitfalls. Diagnostics (Basel) 2020;10:E866. [PMID: 33114057 DOI: 10.3390/diagnostics10110866] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
117 Tu YP, O'Leary TJ. Testing for Severe Acute Respiratory Syndrome-Coronavirus 2: Challenges in Getting Good Specimens, Choosing the Right Test, and Interpreting the Results. Crit Care Med 2020;48:1680-9. [PMID: 32826428 DOI: 10.1097/CCM.0000000000004594] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
118 Chan PKS, Lui G, Hachim A, Ko RLW, Boon SS, Li T, Kavian N, Luk F, Chen Z, Yau EM, Chan KH, Tsang CH, Cheng SMS, Chu DKW, Perera RAPM, Ho WCS, Yeung ACM, Chow C, Poon LLM, Valkenburg SA, Hui DSC, Peiris M. Serologic Responses in Healthy Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020. Emerg Infect Dis 2020;26:3076-8. [PMID: 33089772 DOI: 10.3201/eid2612.203833] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 15.0] [Reference Citation Analysis]
119 Kulkarni R, Patil HP, Palkar S, Lalwani S, Mishra AC, Arankalle V. Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β-propiolactone-inactivated, whole virus-based indirect ELISA. J Virol Methods 2021;287:113996. [PMID: 33126149 DOI: 10.1016/j.jviromet.2020.113996] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
120 Augustine R, Das S, Hasan A, S A, Abdul Salam S, Augustine P, Dalvi YB, Varghese R, Primavera R, Yassine HM, Thakor AS, Kevadiya BD. Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World. J Clin Med 2020;9:E3372. [PMID: 33096742 DOI: 10.3390/jcm9103372] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 17.5] [Reference Citation Analysis]
121 Kurup D, Wirblich C, Ramage H, Schnell MJ. Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2. NPJ Vaccines 2020;5:98. [PMID: 33088593 DOI: 10.1038/s41541-020-00248-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
122 Herzberg J, Vollmer T, Fischer B, Becher H, Becker AK, Sahly H, Honarpisheh H, Guraya SY, Strate T, Knabbe C. Prospective Sero-epidemiological Evaluation of SARS-CoV-2 among Health Care Workers in a German Secondary Care Hospital. Int J Infect Dis 2021;102:136-43. [PMID: 33075538 DOI: 10.1016/j.ijid.2020.10.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
123 Khadke S, Ahmed N, Ahmed N, Ratts R, Raju S, Gallogly M, de Lima M, Sohail MR. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virol J 2020;17:154. [PMID: 33059711 DOI: 10.1186/s12985-020-01415-w] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 27.0] [Reference Citation Analysis]
124 Ferrari M, Paderno A, Giannini L, Cazzador D, Ciardiello C, Carretta G, Piazza C, Nicolai P. COVID-19 screening protocols for preoperative assessment of head and neck cancer patients candidate for elective surgery in the midst of the pandemic: A narrative review with comparison between two Italian institutions. Oral Oncol 2021;112:105043. [PMID: 33129056 DOI: 10.1016/j.oraloncology.2020.105043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
125 Maple PAC, Sikora K. How Useful is COVID-19 Antibody Testing - A Current Assessment for Oncologists. Clin Oncol (R Coll Radiol) 2021;33:e73-81. [PMID: 33350940 DOI: 10.1016/j.clon.2020.10.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
126 Schöler L, Le-Trilling VTK, Eilbrecht M, Mennerich D, Anastasiou OE, Krawczyk A, Herrmann A, Dittmer U, Trilling M. A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds. Front Immunol 2020;11:573526. [PMID: 33162987 DOI: 10.3389/fimmu.2020.573526] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
127 Shirin T, Bhuiyan TR, Charles RC, Amin S, Bhuiyan I, Kawser Z, Rahat A, Alam AN, Sultana S, Aleem MA, Khan MH, Khan SR, LaRocque RC, Calderwood SB, Ryan ET, Slater DM, Banu S, Clemens J, Harris JB, Flora MS, Qadri F. Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh. Int J Infect Dis 2020;101:220-5. [PMID: 33031941 DOI: 10.1016/j.ijid.2020.09.1484] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 16.5] [Reference Citation Analysis]
128 Deshpande GR, Sapkal GN, Tilekar BN, Yadav PD, Gurav Y, Gaikwad S, Kaushal H, Deshpande KS, Kaduskar O, Sarkale P, Baradkar S, Suryawanshi A, Lakra R, Sugunan AP, Balakrishnan A, Abraham P, Salve P. Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients. Indian J Med Res 2020;152:82-7. [PMID: 32859866 DOI: 10.4103/ijmr.IJMR_2382_20] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 21.5] [Reference Citation Analysis]
129 Bosco-Lauth AM, Hartwig AE, Porter SM, Gordy PW, Nehring M, Byas AD, VandeWoude S, Ragan IK, Maison RM, Bowen RA. Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats. Proc Natl Acad Sci U S A 2020;117:26382-8. [PMID: 32994343 DOI: 10.1073/pnas.2013102117] [Cited by in Crossref: 212] [Cited by in F6Publishing: 222] [Article Influence: 106.0] [Reference Citation Analysis]
130 Liu Y, Wang K, Massoud TF, Paulmurugan R. SARS-CoV-2 Vaccine Development: An Overview and Perspectives. ACS Pharmacol Transl Sci 2020;3:844-58. [PMID: 33062951 DOI: 10.1021/acsptsci.0c00109] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
131 da Silva SJR, Silva CTAD, Guarines KM, Mendes RPG, Pardee K, Kohl A, Pena L. Clinical and Laboratory Diagnosis of SARS-CoV-2, the Virus Causing COVID-19. ACS Infect Dis 2020;6:2319-36. [PMID: 32786280 DOI: 10.1021/acsinfecdis.0c00274] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 17.5] [Reference Citation Analysis]
132 Fujigaki H, Takemura M, Osawa M, Sakurai A, Nakamoto K, Seto K, Fujita T, Hata T, Akiyama H, Doi Y, Saito K. Reliability of serological tests for COVID-19: comparison of three immunochromatography test kits for SARS-CoV-2 antibodies. Heliyon 2020;6:e04929. [PMID: 32984615 DOI: 10.1016/j.heliyon.2020.e04929] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
133 Chen Y, Tong X, Li Y, Gu B, Yan J, Liu Y, Shen H, Huang R, Wu C. A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients. PLoS Pathog 2020;16:e1008796. [PMID: 32913364 DOI: 10.1371/journal.ppat.1008796] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 36.5] [Reference Citation Analysis]
134 Hyseni I, Molesti E, Benincasa L, Piu P, Casa E, Temperton NJ, Manenti A, Montomoli E. Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. Viruses 2020;12:E1011. [PMID: 32927639 DOI: 10.3390/v12091011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 20.0] [Reference Citation Analysis]
135 Fong CH, Cai JP, Dissanayake TK, Chen LL, Choi CY, Wong LH, Ng AC, Pang PKP, Ho DT, Poon RW, Chung TW, Sridhar S, Chan KH, Chan JF, Hung IF, Yuen KY, To KK. Improved Detection of Antibodies against SARS-CoV-2 by Microsphere-Based Antibody Assay. Int J Mol Sci 2020;21:E6595. [PMID: 32916926 DOI: 10.3390/ijms21186595] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
136 Wang J, Zhou M. Issues to be considered when planning sero-epidemiological studies in regions with a low incidence of SARS-CoV-2. Am J Infect Control 2020;48:1127-8. [PMID: 32562715 DOI: 10.1016/j.ajic.2020.06.176] [Reference Citation Analysis]
137 Hueston L, Kok J, Guibone A, McDonald D, Hone G, Goodwin J, Carter I, Basile K, Sandaradura I, Maddocks S, Sintchenko V, Gilroy N, Chen S, Dwyer DE, O'Sullivan MVN. The Antibody Response to SARS-CoV-2 Infection. Open Forum Infect Dis 2020;7:ofaa387. [PMID: 32989419 DOI: 10.1093/ofid/ofaa387] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 20.0] [Reference Citation Analysis]
138 Vilibic-Cavlek T, Stevanovic V, Tabain I, Betica-Radic L, Sabadi D, Peric L, Bogdanic M, Vilibic M, Kolaric B, Kudumija B, Petrovic G, Mrzljak A, Karabuva S, Hrstic I, Capak K, Kucinar J, Savic V, Barbic L. Severe acute respiratory syndrome coronavirus 2 seroprevalence among personnel in the healthcare facilities of Croatia, 2020. Rev Soc Bras Med Trop 2020;53:e20200458. [PMID: 32876319 DOI: 10.1590/0037-8682-0458-2020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
139 Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression. Physiology (Bethesda). 2020;35:288-301. [PMID: 32783610 DOI: 10.1152/physiol.00019.2020] [Cited by in Crossref: 88] [Cited by in F6Publishing: 105] [Article Influence: 44.0] [Reference Citation Analysis]
140 Xiao C, Ling S, Qiu M, Deng Z, Chen L, Zhu A, Chen Y, Liu Y, Lin X, Lin F, Wu Q, Shen L, Ye F, Liu X, Li Y, Zhao J, Yang Z, Cowling BJ, Webby R, Zanin M, Wong SS. Human post-infection serological response to the spike and nucleocapsid proteins of SARS-CoV-2. Influenza Other Respir Viruses 2021;15:7-12. [PMID: 32844604 DOI: 10.1111/irv.12798] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
141 Xu M, Wang D, Wang H, Zhang X, Liang T, Dai J, Li M, Zhang J, Zhang K, Xu D, Yu X. COVID-19 diagnostic testing: Technology perspective. Clin Transl Med 2020;10:e158. [PMID: 32898340 DOI: 10.1002/ctm2.158] [Cited by in Crossref: 29] [Cited by in F6Publishing: 41] [Article Influence: 14.5] [Reference Citation Analysis]
142 Klimstra WB, Tilston-Lunel NL, Nambulli S, Boslett J, McMillen CM, Gilliland T, Dunn MD, Sun C, Wheeler SE, Wells A, Hartman AL, McElroy AK, Reed DS, Rennick LJ, Duprex WP. SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients. J Gen Virol 2020;101:1156-69. [PMID: 32821033 DOI: 10.1099/jgv.0.001481] [Cited by in Crossref: 94] [Cited by in F6Publishing: 99] [Article Influence: 47.0] [Reference Citation Analysis]
143 Tan AS, Nerurkar SN, Tan WCC, Goh D, Lai CPT, Poh Sheng Yeong J. The Virological, Immunological, and Imaging Approaches for COVID-19 Diagnosis and Research. SLAS Technol 2020;25:522-44. [PMID: 32808850 DOI: 10.1177/2472630320950248] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
144 Padoan A, Zuin S, Cosma C, Basso D, Plebani M, Bonfante F. Clinical performances of an ELISA for SARS-CoV-2 antibody assay and correlation with neutralization activity. Clin Chim Acta 2020;510:654-5. [PMID: 32818490 DOI: 10.1016/j.cca.2020.08.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
145 Ali SME, Fatima S. Plan for blood banks to protect blood donors and healthcare workers during COVID-19 pandemic. Hematol Transfus Cell Ther 2020;42:316-7. [PMID: 32768365 DOI: 10.1016/j.htct.2020.07.001] [Reference Citation Analysis]
146 Pecora ND, Zand MS. Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning. Clin Lab Med 2020;40:603-14. [PMID: 33121625 DOI: 10.1016/j.cll.2020.08.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
147 Lindahl JF, Hoffman T, Esmaeilzadeh M, Olsen B, Winter R, Amer S, Molnár C, Svalberg A, Lundkvist Å. High seroprevalence of SARS-CoV-2 in elderly care employees in Sweden. Infect Ecol Epidemiol 2020;10:1789036. [PMID: 32939231 DOI: 10.1080/20008686.2020.1789036] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
148 Orth-Höller D, Eigentler A, Weseslindtner L, Möst J. Antibody kinetics in primary- and secondary-care physicians with mild to moderate SARS-CoV-2 infection. Emerg Microbes Infect 2020;9:1692-4. [PMID: 32654611 DOI: 10.1080/22221751.2020.1793690] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
149 Perera RAPM, Tso E, Tsang OTY, Tsang DNC, Fung K, Leung YWY, Chin AWH, Chu DKW, Cheng SMS, Poon LLM, Chuang VWM, Peiris M. SARS-CoV-2 Virus Culture and Subgenomic RNA for Respiratory Specimens from Patients with Mild Coronavirus Disease. Emerg Infect Dis 2020;26:2701-4. [PMID: 32749957 DOI: 10.3201/eid2611.203219] [Cited by in Crossref: 161] [Cited by in F6Publishing: 164] [Article Influence: 80.5] [Reference Citation Analysis]
150 Nagura-ikeda M, Imai K, Kubota K, Noguchi S, Kitagawa Y, Matsuoka M, Tabata S, Miyoshi K, Ito T, Tamura K, Maeda T. Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using the VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan.. [DOI: 10.1101/2020.08.02.20166256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Liu L, To KK, Chan KH, Wong YC, Zhou R, Kwan KY, Fong CH, Chen LL, Choi CY, Lu L, Tsang OT, Leung WS, To WK, Hung IF, Yuen KY, Chen Z. High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerg Microbes Infect 2020;9:1664-70. [PMID: 32618497 DOI: 10.1080/22221751.2020.1791738] [Cited by in Crossref: 94] [Cited by in F6Publishing: 80] [Article Influence: 47.0] [Reference Citation Analysis]
152 Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E, Vandecandelaere P, Indevuyst C, Depypere M, Desmet S, André E, Van Ranst M, Lagrou K, Vermeersch P. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clin Microbiol Infect 2020;26:1557.e1-7. [PMID: 32745595 DOI: 10.1016/j.cmi.2020.07.038] [Cited by in Crossref: 97] [Cited by in F6Publishing: 102] [Article Influence: 48.5] [Reference Citation Analysis]
153 Perera RA, Ko R, Tsang OT, Brackman CJ, To EMW, Yen H, Leung K, Cheng SM, Chan KH, Chan KC, Li K, Saif L, Barrs VR, Wu JT, Sit THC, Poon LL, Peiris M. Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat and hamster sera.. [DOI: 10.1101/2020.07.28.20163592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
154 Qin X, Shen J, Dai E, Li H, Tang G, Zhang L, Hou X, Lu M, Wu X, Duan S, Zhang J, Li Y. The change pattern and significance of IgM and IgG in the progress of COVID-19 disease.. [DOI: 10.1101/2020.07.20.20157446] [Reference Citation Analysis]
155 Zhou T, Teng IT, Olia AS, Cerutti G, Gorman J, Nazzari A, Shi W, Tsybovsky Y, Wang L, Wang S, Zhang B, Zhang Y, Katsamba PS, Petrova Y, Banach BB, Fahad AS, Liu L, Acevedo SNL, Madan B, de Souza MO, Pan X, Wang P, Wolfe JR, Yin M, Ho DD, Phung E, DiPiazza A, Chang L, Abiona O, Corbett KS, DeKosky BJ, Graham BS, Mascola JR, Misasi J, Ruckwardt T, Sullivan NJ, Shapiro L, Kwong PD. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. SSRN 2020;:3639618. [PMID: 32742241 DOI: 10.2139/ssrn.3639618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
156 Ko JH, Joo EJ, Park SJ, Baek JY, Kim WD, Jee J, Kim CJ, Jeong C, Kim YJ, Shon HJ, Kang ES, Choi YK, Peck KR. Neutralizing Antibody Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 Patients. J Clin Med 2020;9:E2268. [PMID: 32708872 DOI: 10.3390/jcm9072268] [Cited by in Crossref: 82] [Cited by in F6Publishing: 85] [Article Influence: 41.0] [Reference Citation Analysis]
157 Haselmann V, Kittel M, Gerhards C, Thiaucourt M, Eichner R, Costina V, Neumaier M. Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples. Clin Chim Acta 2020;510:73-8. [PMID: 32652161 DOI: 10.1016/j.cca.2020.07.007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 17.5] [Reference Citation Analysis]
158 Weidner L, Gänsdorfer S, Unterweger S, Weseslindtner L, Drexler C, Farcet M, Witt V, Schistal E, Schlenke P, Kreil TR, Jungbauer C. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays. J Clin Virol 2020;129:104540. [PMID: 32652475 DOI: 10.1016/j.jcv.2020.104540] [Cited by in Crossref: 124] [Cited by in F6Publishing: 121] [Article Influence: 62.0] [Reference Citation Analysis]
159 Peng M. Outbreak of COVID-19: An emerging global pandemic threat. Biomed Pharmacother 2020;129:110499. [PMID: 32768974 DOI: 10.1016/j.biopha.2020.110499] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
160 Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui LP, Johnston JC, Lan Z, Law S, MacLean E, Trajman A, Menzies D, Benedetti A, Ahmad Khan F. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ 2020;370:m2516. [PMID: 32611558 DOI: 10.1136/bmj.m2516] [Cited by in Crossref: 471] [Cited by in F6Publishing: 514] [Article Influence: 235.5] [Reference Citation Analysis]
161 Fujigaki H, Takemura M, Osawa M, Sakurai A, Nakamoto K, Setod K, Fujita T, Hata T, Akiyama H, Doi Y, Saito K. Reliability of serological tests for COVID-19: Comparison of three immunochromatography test kits for SARS-CoV-2 antibodies.. [DOI: 10.1101/2020.06.28.20140475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
162 Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, Cornaby C, Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Rouphael N, Edupuganti S, Weiskopf D, Tse LV, Hou YJ, Margolis D, Sette A, Collins MH, Schmitz J, Baric RS, de Silva AM. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol 2020;5:eabc8413. [PMID: 32527802 DOI: 10.1126/sciimmunol.abc8413] [Cited by in Crossref: 560] [Cited by in F6Publishing: 568] [Article Influence: 280.0] [Reference Citation Analysis]
163 Rohn H, Feldkamp T, Witzke O. [COVID-19 and the kidneys]. Nephrologe 2020;:1-6. [PMID: 32837571 DOI: 10.1007/s11560-020-00444-4] [Reference Citation Analysis]
164 Choe PG, Kang CK, Suh HJ, Jung J, Kang E, Lee SY, Song KH, Kim HB, Kim NJ, Park WB, Kim ES, Oh MD. Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients. Emerg Infect Dis 2020;26:2484-7. [PMID: 32579877 DOI: 10.3201/eid2610.202211] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 26.5] [Reference Citation Analysis]
165 Zhou T, Teng IT, Olia AS, Cerutti G, Gorman J, Nazzari A, Shi W, Tsybovsky Y, Wang L, Wang S, Zhang B, Zhang Y, Katsamba PS, Petrova Y, Banach BB, Fahad AS, Liu L, Lopez Acevedo SN, Madan B, de Souza MO, Pan X, Wang P, Wolfe JR, Yin M, Ho DD, Phung E, DiPiazza A, Chang L, Abiona O, Corbett KS, DeKosky BJ, Graham BS, Mascola JR, Misasi J, Ruckwardt T, Sullivan NJ, Shapiro L, Kwong PD. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. bioRxiv 2020:2020. [PMID: 32596696 DOI: 10.1101/2020.06.22.166033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
166 Ayouba A, Thaurignac G, Morquin D, Tuaillon E, Raulino R, Nkuba A, Lacroix A, Vidal N, Foulongne V, Le Moing V, Reynes J, Delaporte E, Peeters M. Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV. J Clin Virol 2020;129:104521. [PMID: 32623350 DOI: 10.1016/j.jcv.2020.104521] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 22.0] [Reference Citation Analysis]
167 Klimstra WB, Tilston-Lunel NL, Nambulli S, Boslett J, McMillen CM, Gilliland T, Dunn MD, Sun C, Wheeler SE, Wells A, Hartman AL, McElroy AK, Reed DS, Rennick LJ, Duprex WP. SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected, hospitalized COVID-19 patients. bioRxiv 2020:2020. [PMID: 32607507 DOI: 10.1101/2020.06.19.154930] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
168 Acuti Martellucci C, Flacco ME, Cappadona R, Bravi F, Mantovani L, Manzoli L. SARS-CoV-2 pandemic: An overview. Adv Biol Regul 2020;77:100736. [PMID: 32773099 DOI: 10.1016/j.jbior.2020.100736] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 16.5] [Reference Citation Analysis]
169 La Marca A, Capuzzo M, Paglia T, Roli L, Trenti T, Nelson SM. Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reprod Biomed Online 2020;41:483-99. [PMID: 32651106 DOI: 10.1016/j.rbmo.2020.06.001] [Cited by in Crossref: 227] [Cited by in F6Publishing: 243] [Article Influence: 113.5] [Reference Citation Analysis]
170 Schöler L, Le-trilling VTK, Eilbrecht M, Mennerich D, Anastasiou OE, Krawczyk A, Herrmann A, Dittmer U, Trilling M. A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.. [DOI: 10.1101/2020.06.05.135806] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
171 Tuaillon E, Bolloré K, Pisoni A, Debiesse S, Renault C, Marie S, Groc S, Niels C, Pansu N, Dupuy AM, Morquin D, Foulongne V, Bourdin A, Le Moing V, Van de Perre P. Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients. J Infect 2020;81:e39-45. [PMID: 32504735 DOI: 10.1016/j.jinf.2020.05.077] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 34.5] [Reference Citation Analysis]
172 Zhang Y, Leung K, Perera RAPM, Lee CK, Peiris JSM, Wu JT. Harnessing the potential of blood donation archives for influenza surveillance and control. PLoS One 2020;15:e0233605. [PMID: 32470010 DOI: 10.1371/journal.pone.0233605] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
173 Bosco-lauth AM, Hartwig AE, Porter SM, Gordy PW, Nehring M, Byas AD, Vandewoude S, Ragan IK, Maison RM, Bowen RA. Pathogenesis, transmission and response to re-exposure of SARS-CoV-2 in domestic cats.. [DOI: 10.1101/2020.05.28.120998] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
174 Fong CH, Cai J, Dissanayake TK, Chen L, Choi CY, Wong L, Ng AC, Pang PK, Ho DT, Poon RW, Chung TW, Sridhar S, Chan K, Chan JF, Hung IF, Yuen K, To KK. Improved detection of antibody against SARS-CoV-2 by microsphere-based antibody assay.. [DOI: 10.1101/2020.05.26.20113191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
175 Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, Xie X, Shi PY. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. bioRxiv 2020:2020. [PMID: 32511386 DOI: 10.1101/2020.05.21.109546] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
176 Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, Cordes S, Ross B, Esser S, Lindemann M, Kribben A, Dittmer U, Witzke O, Herrmann A. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. J Clin Virol 2020;128:104437. [PMID: 32434708 DOI: 10.1016/j.jcv.2020.104437] [Cited by in Crossref: 260] [Cited by in F6Publishing: 197] [Article Influence: 130.0] [Reference Citation Analysis]
177 Montague Z, Lv H, Otwinowski J, Dewitt WS, Isacchini G, Yip GK, Ng WW, Tsang OT, Yuan M, Liu H, Wilson I, Peiris JM, Wu NC, Nourmohammad A, Mok CKP. Dynamics of B-Cell Repertoires and Emergence of Cross-Reactive Responses in COVID-19 Patients with Different Disease Severity. SSRN Journal. [DOI: 10.2139/ssrn.3751051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]